Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1994 Mar;69(3):617–619. doi: 10.1038/bjc.1994.115

Stimulation of erythropoiesis by the non-steroidal anti-androgen nilutamide in men with prostate cancer: evidence for an agonistic effect?

A Decensi 1, R Torrisi 1, V Fontana 1
PMCID: PMC1968859  PMID: 8123500

Abstract

The effects of steroid hormones are pleiotropic. Similarly, non-steroidal oestrogen receptor antagonists such as tamoxifen exert partial agonistic effects with a species- and tissue-specific pattern. Conversely, little is known of the biological effects of non-steroidal anti-androgens, whose role has been investigated in the palliative treatment of prostate cancer. We studied the effects of the non-steroidal anti-androgen nilutamide on parameters of red blood cells, an androgen-dependent cell compartment, in 24 men with prostate cancer and compared the results with those obtained in 38 historical control patients treated with D-tryptophan-6-LHRH. Administration of the anti-androgen induced a limited rise in testosterone concentrations (from 14.1 +/- 1.8 up to a maximum of 19.6 +/- 2.3 nmol l-1) and a significant increase with time in haemoglobin and haematocrit (y = 12.6 g dl-1 + 0.15 months and y = 37.3% + 0.46 months respectively, P = 0.008 for both), while no change occurred in red blood cell count (y = 4.19 x 10(6) mm-3 + 0.02 months, P = 0.2). Conversely, no variation in erythroid parameters was observed in the patients treated with the LHRH analogue (haemoglobin = 12.7 + 0.02 months, P = 0.59; haematocrit = 38.1 + 0.02 months, P = 0.9; red blood cells = 4.34 x 10(6) mm-3 + 0.15 months, P = 0.4). The difference between the linear regression slopes of haemoglobin in the two treatment groups was significant (F-ratio = 3.39, P = 0.03). While the stimulation of erythropoiesis induced by the anti-androgen might be due to incomplete neutralisation of endogenous androgens at the bone marrow level, a cell-specific agonistic effect of the drug cannot be excluded, thus calling into question the designation of pure antagonists which has been attributed to this class of compounds. Ongoing randomised trials should address this issue.

Full text

PDF
617

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Benson R. C. A rationale for the use of non-steroidal anti-androgens in the management of prostate cancer. Prostate Suppl. 1992;4:85–90. doi: 10.1002/pros.2990210513. [DOI] [PubMed] [Google Scholar]
  2. Berry M., Metzger D., Chambon P. Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. EMBO J. 1990 Sep;9(9):2811–2818. doi: 10.1002/j.1460-2075.1990.tb07469.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Boccardo F., Decensi A., Guarneri D., Rubagotti A., Massa T., Martorana G., Giberti C., Cerruti G. B., Tani F., Zanollo A. Long-term results with a long-acting formulation of D-TRP-6 LH-RH in patients with prostate cancer: an Italian prostatic cancer project (P.O.N.CA.P.) study. Prostate. 1987;11(3):243–255. doi: 10.1002/pros.2990110305. [DOI] [PubMed] [Google Scholar]
  4. Claustres M., Sultan C. Androgen and erythropoiesis: evidence for an androgen receptor in erythroblasts from human bone marrow cultures. Horm Res. 1988;29(1):17–22. doi: 10.1159/000180959. [DOI] [PubMed] [Google Scholar]
  5. Crawford E. D., Fair W. R., Kelloff G. J., Lieber M. M., Miller G. J., Scardíno P. T., DeAntoni E. P. Chemoprevention of prostate cancer: guidelines for possible intervention strategies. J Cell Biochem Suppl. 1992;16H:140–145. doi: 10.1002/jcb.240501232. [DOI] [PubMed] [Google Scholar]
  6. Decensi A. U., Boccardo F., Guarneri D., Positano N., Paoletti M. C., Costantini M., Martorana G., Giuliani L. Monotherapy with nilutamide, a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. The Italian Prostatic Cancer Project. J Urol. 1991 Aug;146(2):377–381. doi: 10.1016/s0022-5347(17)37799-6. [DOI] [PubMed] [Google Scholar]
  7. Decensi A., Torrisi R., Fontana V., Marroni P., Padovani P., Guarneri D., Minuto F., Boccardo F. Long-term endocrine effects of administration of either a non-steroidal antiandrogen or a luteinizing hormone-releasing hormone agonist in men with prostate cancer. Acta Endocrinol (Copenh) 1993 Oct;129(4):315–321. doi: 10.1530/acta.0.1290315. [DOI] [PubMed] [Google Scholar]
  8. Fried W., Morley C. Effects of androgenic steroids on erythropoiesis. Steroids. 1985 Oct-Nov;46(4-5):799–826. doi: 10.1016/0039-128x(85)90031-5. [DOI] [PubMed] [Google Scholar]
  9. Gooren L., Spinder T., Spijkstra J. J., van Kessel H., Smals A., Rao B. R., Hoogslag M. Sex steroids and pulsatile luteinizing hormone release in men. Studies in estrogen-treated agonadal subjects and eugonadal subjects treated with a novel nonsteroidal antiandrogen. J Clin Endocrinol Metab. 1987 Apr;64(4):763–770. doi: 10.1210/jcem-64-4-763. [DOI] [PubMed] [Google Scholar]
  10. Green S. Modulation of oestrogen receptor activity by oestrogens and anti-oestrogens. J Steroid Biochem Mol Biol. 1990 Dec 20;37(6):747–751. doi: 10.1016/0960-0760(90)90415-h. [DOI] [PubMed] [Google Scholar]
  11. Gronemeyer H. Control of transcription activation by steroid hormone receptors. FASEB J. 1992 May;6(8):2524–2529. doi: 10.1096/fasebj.6.8.1592204. [DOI] [PubMed] [Google Scholar]
  12. Janknegt R. A., Abbou C. C., Bartoletti R., Bernstein-Hahn L., Bracken B., Brisset J. M., Da Silva F. C., Chisholm G., Crawford E. D., Debruyne F. M. Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. J Urol. 1993 Jan;149(1):77–83. doi: 10.1016/s0022-5347(17)36003-2. [DOI] [PubMed] [Google Scholar]
  13. Kelly W. K., Scher H. I. Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol. 1993 Mar;149(3):607–609. doi: 10.1016/s0022-5347(17)36163-3. [DOI] [PubMed] [Google Scholar]
  14. Landers J. P., Spelsberg T. C. New concepts in steroid hormone action: transcription factors, proto-oncogenes, and the cascade model for steroid regulation of gene expression. Crit Rev Eukaryot Gene Expr. 1992;2(1):19–63. [PubMed] [Google Scholar]
  15. Marcondes J. A., Minnani S. L., Luthold W. W., Wajchenberg B. L., Samojlik E., Kirschner M. A. Treatment of hirsutism in women with flutamide. Fertil Steril. 1992 Mar;57(3):543–547. doi: 10.1016/s0015-0282(16)54897-3. [DOI] [PubMed] [Google Scholar]
  16. Moguilewsky M., Fiet J., Tournemine C., Raynaud J. P. Pharmacology of an antiandrogen, anandron, used as an adjuvant therapy in the treatment of prostate cancer. J Steroid Biochem. 1986 Jan;24(1):139–146. doi: 10.1016/0022-4731(86)90043-9. [DOI] [PubMed] [Google Scholar]
  17. Nayfield S. G., Karp J. E., Ford L. G., Dorr F. A., Kramer B. S. Potential role of tamoxifen in prevention of breast cancer. J Natl Cancer Inst. 1991 Oct 16;83(20):1450–1459. doi: 10.1093/jnci/83.20.1450. [DOI] [PubMed] [Google Scholar]
  18. Poyet P., Labrie F. Comparison of the antiandrogenic/androgenic activities of flutamide, cyproterone acetate and megestrol acetate. Mol Cell Endocrinol. 1985 Oct;42(3):283–288. doi: 10.1016/0303-7207(85)90059-0. [DOI] [PubMed] [Google Scholar]
  19. Schwall R., Schmelzer C. H., Matsuyama E., Mason A. J. Multiple actions of recombinant activin-A in vivo. Endocrinology. 1989 Sep;125(3):1420–1423. doi: 10.1210/endo-125-3-1420. [DOI] [PubMed] [Google Scholar]
  20. Sogani P. C., Vagaiwala M. R., Whitmore W. F., Jr Experience with flutamide in patients with advanced prostatic cancer without prior endocrine therapy. Cancer. 1984 Aug 15;54(4):744–750. doi: 10.1002/1097-0142(1984)54:4<744::aid-cncr2820540426>3.0.co;2-p. [DOI] [PubMed] [Google Scholar]
  21. Steinsapir J., Mora G., Muldoon T. G. Effects of steroidal and non-steroidal antiandrogens on the androgen binding properties of the rat ventral prostate androgen receptor. Biochim Biophys Acta. 1991 Aug 13;1094(1):103–112. doi: 10.1016/0167-4889(91)90031-r. [DOI] [PubMed] [Google Scholar]
  22. Weber J. P., Walsh P. C., Peters C. A., Spivak J. L. Effect of reversible androgen deprivation on hemoglobin and serum immunoreactive erythropoietin in men. Am J Hematol. 1991 Mar;36(3):190–194. doi: 10.1002/ajh.2830360306. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES